查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球正压通气 (PAP) 设备市场
市场调查报告书
商品编码
1140754

2022-2029 年全球正压通气 (PAP) 设备市场

Global Positive Airway Pressure (PAP) Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

睡眠呼吸暂停综合征的增加推动市场增长

睡眠呼吸暂停综合征是由于睡眠时呼吸受到干扰而引起的呼吸系统疾病，常见于肥胖人群和糖尿病患者。阻塞性睡眠呼吸暂停 (OSA) 是睡眠期间的部分和完全气道阻塞。严重程度由呼吸暂停低通气指数 (AHI) 计算，该指数是每小时睡眠中呼吸暂停低通气发作的平均次数。

近年来，阻塞性睡眠呼吸暂停 (OSA) 呈上升趋势。根据 Statista 2021 年数据，到 2028 年，全球睡眠呼吸暂停治疗和诊断市场规模预计将达到 82.4 亿美元。其中超过 32 亿美元预计将发生在北美。该统计数据按地区显示了自 2018 年以来全球睡眠呼吸暂停治疗和诊断市场的规模，并包括到 2028 年的预测。睡眠呼吸暂停是一种医疗状况，其中患者的呼吸模式在睡眠期间减少或停止。不健康的生活习惯增加了阻塞性睡眠呼吸暂停的患病率。成人睡眠障碍的预期患病率正在增加。因此，睡眠呼吸暂停患病率的上升预计将增加对 PAP 设备的需求。

然而，全球气道正压通气 (PAP) 设备的市场增长可能会受到与 PAP 机器相关的高成本的阻碍。例如，持续气道正压通气 (CPAP) 设备的平均成本在 250 美元到 1,000 美元之间，具体取决于品牌、机器型号和功能。然而，由于睡眠呼吸暂停治疗由健康保险承保，患者必须承担总费用的一部分。此外，用于旅行的新上市便携式 CPAP 设备被视为奢侈品，不在任何保险范围内。

区域渗透率。

北美是预测期内的主要地区。

按地区划分，气道正压通气 (PAP) 设备的全球市场分为北美、欧洲、亚太地区、拉丁美洲、中东和非洲。

由于该地区阻塞性睡眠呼吸暂停综合征的患病率不断上升，北美在 2021 年占全球气道正压通气 (PAP) 设备市场的最大市场份额。例如，根据美国国家睡眠基金会的数据，到 2021 年，阻塞性睡眠呼吸暂停是美国最常见的睡眠呼吸暂停类型。据估计，它会影响美国 10% 至 30% 的面临阻塞性睡眠呼吸暂停的成年人，但它通常仍未得到诊断。PAP 设备的需求量很大，因为它们具有调节压力的能力，并且可以根据患者的需求和睡眠阶段进行自动调整。此外，美国保险公司提供的优惠报销政策有力地支持了该地区 PAP 设备的增长。这导致更多的患者选择治疗睡眠呼吸暂停，并显着增加了 PAP 设备的采用。糖尿病和肥胖症患病率的上升也有望刺激市场增长。

亚太地区睡眠呼吸暂停发病率高，日本循环学会、中国睡眠学会等政府主导的支持力度加大，以提高该地区对睡眠呼吸暂停的认识，预计增长最快预测期内的利率。此外，中国、日本和印度的产品发布、批准和与国际公司的合作伙伴关係都在增加。

竞争格局。

气道正压通气 (PAP) 设备市场的主要参与者包括 Koninklijke Philips NV (Philips Respironics)、ResMed、Fisher and Paykel Healthcare Limited、DeVilbiss Healthcare Inc 和 Smiths Medical、3B Medical。领先的公司正在采取多种增长战略，例如产品发布、收购和合作伙伴关係，为全球气道正压通气 (PAP) 设备市场的增长做出了贡献。2022年1月，ICU Medical完成了对Smiths Group plc的Smiths Medical的收购。此次收购已与 ICU Medical 的现有业务整合。合併后的公司创建了一家领先的输液治疗公司，预计综合收入约为 25 亿美元。2021年12月，全球医疗技术领导者菲利普收购美国医疗技术公司Vesper Medical，以扩大其影像引导治疗设备产品组合。Vesper Medical 计划通过其用于治疗深静脉疾病的先进静脉支架产品组合进一步扩展飞利浦的诊断和治疗设备产品组合。此次收购有助于扩大血管治疗领域。2021 年 6 月，Phillips在美国召回了 Bi-Level PAP、CPAP 和机械呼吸机。2022年5月，全球医疗技术领导者Medtronic完成了对Intersect ENT的收购。此次收购扩大了公司全面的耳鼻喉 (ENT) 产品组合，包括改善术后结果和治疗用于鼻窦手术的鼻息肉等创新产品。

COVID-19 的影响会对气道正压通气 (PAP) 设备产生积极影响。

COVID-19 正在影响全球经济，直接影响生产和需求、供应链中断和市场中断，以及对企业和金融市场的财务影响。

由于 COVID-19 大流行的危机，在 FDA 最近的紧急政策之后，持续气道正压通气 (CPAP) 作为救生呼吸机的替代品开始获得更多的认可。随着 COVID-19 疫情的发展，全球呼吸机价格居高不下，表明严重短缺。2020 年 6 月，研发和製造持续气道正压通气 (CPAP) 的医疗器械公司 Apex Medical Corp. 推出了 CPAP 产品和新设计的导管的集成解决方案，用于治疗轻度和中度 COVID。-19 名患者将获得另一个呼吸治疗方案。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查目的和范围

第二章市场定义和概述

第三章执行摘要

  • 按类型划分的市场细分
  • 最终用户的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
  • 促进者
    • 装置技术进步
  • 抑製剂
    • 严格的监管审批
  • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措
  • 概括

第 7 章 按类型

  • 自动气道正压通气 (APAP) 装置
  • 双水平气道正压通气 (BiPAP) 装置
  • 持续气道正压通气 (CPAP) 机

第 8 章最终用户

  • 医院
  • 睡眠研究所
  • 家庭医疗
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 10 章 竞争格局

  • 竞争情景
  • 市场/份额分析
  • 併购分析

第十一章公司简介

  • Smiths Medical
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务概览
  • Koninklijke Philips N.V.
  • Devilbiss Healthcare LLC
  • Medtronic Plc.
  • Draegerwerk AG & Co. KGaA
  • 3B Medical, Inc.
  • ResMed Inc.
  • Fisher & Paykel Healthcare Limited
  • Lowenstein Medical UK Ltd.
  • APEX MEDICAL CORP.（List Not Exhaustive）

第 12 章 数据管理

简介目录
Product Code: DMPH2858

Market Overview

Positive Airway Pressure (PAP) Devices Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.5 % during the forecast period (2022-2029).

Positive airway pressure (PAP), such as continuous PAP (CPAP) or bilevel PAP (BPAP), is used to treat breathing disordered during sleep, such as Obstructive Sleep Apnea (OSA), Central Sleep Apnea (CSA) or hypoventilation (as may be seen in patients with Obesity Hypoventilation Syndrome, COPD, or neuromuscular diseases). The global positive airway pressure (PAP) Devices market growth is driven by factors such as the rising prevalence of sleep apnea, rising collaborations, and increasing R&D investments toward developing technologically-advanced devices.

Market Dynamics: Rising prevalence of sleep apnea is driving the market growth

Sleep Apnea is a respiratory disorder caused due to disruption of breathing during sleeping commonly observed in obese people and diabetes patients, resulting in loud snoring due to blockage of air during breathing. Obstructive sleep apnea (OSA) is the partial and complete airway obstructions that occur while sleeping. The severity of the disease is calculated with an apnea-hypopnea index (AHI which is the mean number of apneas and hypopneas per hour of sleep.

Obstructive sleep apnea (OSA) has increased over the past few years. According to Statista data 2021, the total global market size for sleep apnea therapeutics and diagnostics was expected to reach 8.24 billion U.S. dollars by 2028. Over 3.2 billion dollars was forecast to be generated in North America. This statistic represents the sleep apnea therapeutics and diagnostics market size worldwide by region since 2018, with projections up to 2028. Sleep apnea is a medical condition in which the patient's breathing patterns during sleep decrease or even stop. The prevalence of obstructive sleep apnea is growing due to an unhealthy lifestyle. The anticipated prevalence of sleep-disordered disorders has grown in adults. Hence, the rising prevalence of sleep apnea is anticipated to rise the demand for PAP devices.

However, the global positive airway pressure (PAP) Devices market growth is likely to be hampered by the high cost associated with PAP machines. For instance, the average cost of continuous positive airway pressure (CPAP) device varies between $250 to $1,000, depending on the brand, machine model, and feature. However, health insurance covers the cost of sleep apnea treatment; patients must bear some part of the total cost. Also, the portable travel-friendly CPAP devices newly launched in the market are considered merely luxury items and are not covered by any insurance coverage.

Market Segmentation: The CPAP Segment is projected to be the dominant segment in the market during the forecast period.

Based on product type, the global market for PAP devices is classified into Automatic Positive Airway Pressure (APAP) Devices, Bilevel Positive Airway Pressure (BiPAP) Devices, and Continuous Positive Airway Pressure (CPAP) Devices.

The CPAP devices accounted for the largest market share and are anticipated to grow significantly over the forecast period. Continuous Positive Airway Pressure (CPAP) Devices are the first line of treatment for obstructive sleep apnea. They are prescribed to a patient suffering from snoring and episodes of obstructed breathing during sleep. In addition, increased adoption of these devices due to their low cost compared to other PAP devices has supported the growth of this segment.

On the other hand, the Bilevel Positive Airway Pressure (BiPAP) devices segment is expected to grow at the fastest rate over the forecast period. This device is recommended for patients with difficulty exhaling while using a CPAP device. The device has an advantage over CPAP devices, which is more efficient in the breathing pattern of patients as it provides an alternate/variable flow of air. Also, the accessibility of reasonable reimbursement and the availability of technologically advanced products are some of the key factors expected to drive the growth of this segment over the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

In terms of region, the global Positive Airway Pressure (PAP) Devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America accounted for the largest market share of the global positive airway pressure (PAP) devices market in 2021, owing to the rising prevalence of obstructive sleep apnea in this region. For instance, according to National Sleep Foundation in 2021, in the U.S, Obstructive sleep apnea is the most common type of sleep apnea. It is estimated to affect 10% to 30% of adults in the United States facing obstructive sleep apnea but, in many cases, goes undiagnosed. There is high demand for PAP devices as they have the facility of adjusting pressure, and auto adjustments can be made based on the patient's need and sleep stage. Moreover, favorable reimbursement policies offered by insurance providers in the U.S. have strongly supported the growth of PAP devices in this region. This, in turn, has encouraged the patients to opt for sleep apnea treatment, which has led to a significant increase in the adoption of PAP devices. Besides, the growing prevalence of diabetes and obesity is likely to fuel market growth.

The Asia Pacific is expected to grow at the fastest growth rate over the forecast period due to the high prevalence of sleep apnea diseases and increasing support from government initiatives, like the Japanese Circulation Society and Chinese Sleep Research Society, to create awareness of sleep apnea disorders in this region. In addition, increasing product launches, approvals, and collaborations by international players in China, Japan and India.

Competitive Landscape:

Some of the major players in the positive airway pressure (PAP) devices market include Koninklijke Philips N.V. (Philips Respironics), ResMed, Fisher and Paykel Healthcare Limited, DeVilbiss Healthcare Inc., and Smiths Medical, 3B Medical, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global positive airway pressure (PAP) devices market. In January 2022, ICU Medical completed the acquisition of Smiths Medical from Smiths Group plc. Through this acquisition, they combined with ICU Medical's existing businesses; the combined companies created a leading infusion therapy company with estimated pro forma combined revenues of approximately $2.5 billion. In December 2021, Philip, a global leader in health technology, expanded its image-guided therapy devices portfolio by acquiring Vesper Medical, a US-based medical technology company. Vesper Medical will further expand Philips' portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for treating deep venous disease. This acquisition helped expand the vascular therapy space. In June 2021, Philips recalled Bi-Level PAP, CPAP, and mechanical ventilator devices in the United States. In May 2022, Medtronic, a global leader in healthcare technology, completed the acquisition of Intersect ENT. This acquisition helps to expand the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve postoperative outcomes and treat nasal polyps.

COVID-19 Impact: Positive impact on the positive airway pressure (PAP) devices.

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.

Due to the COVID-19 pandemic crisis, continuous positive airway pressure (CPAP) has started witnessing greater preference as a potential replacement for lifesaving ventilators after the FDA's recent emergency policy. As the COVID-19 pandemic continues to develop, the global price of ventilators is high and seriously inadequate. In June 2020, Apex Medical Corp., the medical device company, who develops and manufactures the continuous positive airway pressure machine (CPAP), has launched the integrated solution of its CPAP product with the new catheter design to provide mild and moderate COVID-19 patients with another respiratory treatment program.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by End-User
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Technological Advancements In Devices
    • 4.2.2. XX
  • 4.3. Restraints
    • 4.3.1. Stringent regulatory approvals
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Automatic Positive Airway Pressure (APAP) Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Bilevel Positive Airway Pressure (BiPAP) Devices
  • 7.4. Continuous Positive Airway Pressure (CPAP) Devices

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User Segment
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Sleep Laboratories
  • 8.4. Home Care
  • 8.5. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Smiths Medical*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Koninklijke Philips N.V.
  • 11.3. Devilbiss Healthcare LLC
  • 11.4. Medtronic Plc.
  • 11.5. Draegerwerk AG & Co. KGaA
  • 11.6. 3B Medical, Inc.
  • 11.7. ResMed Inc.
  • 11.8. Fisher & Paykel Healthcare Limited
  • 11.9. Lowenstein Medical UK Ltd.
  • 11.10. APEX MEDICAL CORP. (List Not Exhaustive)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us